Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IPF World Week

The 5 W’s of Virtual Patient Engagement

Learn the Who, What, When, Where, and Why (+ How) of virtual patient engagement programs...

Impetus Digital

- PMLiVE

Roche’s spinal muscular atrophy therapy recommended by CHMP for newborns

Evrysdi is already approved in the EU to treat SMA patients aged two months or older

- PMLiVE

Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn

Zilebesiran is in phase 2 development to treat hypertension in patients with high-unmet needs

- PMLiVE

Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial

The therapy is already approved for certain MS patients as a twice-yearly intravenous infusion

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

- PMLiVE

Roche’s Evrysdi shows continued improvement in children with spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies

Katherine Tupper and Holly Joscelyne's top takeaways from the Patients as Partners conference 2023

Patients as Partners – putting people first in clinical trials

Cuttsy+Cuttsy's key takeaways from the Patients as Partners conference 2023

Cuttsy + Cuttsy

- PMLiVE

Roche’s fixed-duration lymphoma treatment granted FDA accelerated approval

Globally around 160,000 people are diagnosed with non-Hodgkin's lymphoma each year

From Multichannel to Omnichannel

Take a look at the movement to omnichannel communication

Mednet Group

Patient Clinical Trial & Communications Plan Review: A Customer Story

Our client reached out to Impetus to help establish a virtual patient panel with the aim to gather insights on their unmet needs, the most important attributes of treatment, and the impact of...

Impetus Digital

- PMLiVE

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

About 100,000 people are living with the progressive condition in the US alone

- PMLiVE

Roche reports positive results for drug for relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links